Yess!! Ihub has a bunch of commies running their site...I got banned from OWCP board too, there's just too many immature posters. Anyways, not sure if any of you guys checked this out yet, but OWCP and Sheba have already begun clinical research for Multiple Myeloma!! This is a HUGE step. Another awesome upcoming catalyst for us longs...here's the link.
Cannabinoids: Italian research leading to the first trial worldwide on patients with multiple myeloma
The results from an Italian research have led the Israeli-American pharmaceutical company One World Cannabis Pharmaceutical (OWCP), in collaboration with Sheba Academic Medical Center, to start the first trial ever on cannabinoids in patients with multiple myeloma, a rare blood cancer affecting immune system cells.
The Israeli-Americans have started from the promising work of the research team working at the General Pathology and Immunology Department of the University of Camerino led by Prof. Giorgio Santoni, finding the study coordinated by Massimo Nabissi (pictured) particularly interesting. The study started in 2013 in collaboration with the Department of Haematology of Ospedali Riuniti in Ancona and observed the cannabinoid receptor expression in patient cancer plasmacells in order to verify if these cells could be “targeted” by the cannabinoid action.
“After the Ethics Committee approved the trial – explained Nabissi, highlighting the difference between medical and recreational use of cannabis – we recruited patients and started the study with the purpose of verifying if the treatment with Cannabidiol (CBD) in combination with a drug currently used in the treatment of myeloma could be increasingly effective on cancer cells and if the use of CBD could reduce chemotherapy”.
The promising results of the Italian research team were published in 2015 in the prestigious scientific journal “International Journal of Cancer”, and profitably stimulated the attention of the American company that decided to use, in their trial, the combination of drugs used by Camerino researchers in this study.
“The use of cannabinoids – continues Nabissi – is now considered effective in various diseases, including chronic pain, but it is also used as an antiemetic to reduce vomiting in patients undergoing chemotherapy, as anti-anorectic in the stimulation of appetite in patients with anorexia, as well as in some forms of glaucoma and in Multiple Sclerosis”.
https://www.researchitaly.it/en/success-stori...e-myeloma/
Cannabinoids: Italian research leading to the first trial worldwide on patients with multiple myeloma
The results from an Italian research have led the Israeli-American pharmaceutical company One World Cannabis Pharmaceutical (OWCP), in collaboration with Sheba Academic Medical Center, to start the first trial ever on cannabinoids in patients with multiple myeloma, a rare blood cancer affecting immune system cells.
The Israeli-Americans have started from the promising work of the research team working at the General Pathology and Immunology Department of the University of Camerino led by Prof. Giorgio Santoni, finding the study coordinated by Massimo Nabissi (pictured) particularly interesting. The study started in 2013 in collaboration with the Department of Haematology of Ospedali Riuniti in Ancona and observed the cannabinoid receptor expression in patient cancer plasmacells in order to verify if these cells could be “targeted” by the cannabinoid action.
“After the Ethics Committee approved the trial – explained Nabissi, highlighting the difference between medical and recreational use of cannabis – we recruited patients and started the study with the purpose of verifying if the treatment with Cannabidiol (CBD) in combination with a drug currently used in the treatment of myeloma could be increasingly effective on cancer cells and if the use of CBD could reduce chemotherapy”.
The promising results of the Italian research team were published in 2015 in the prestigious scientific journal “International Journal of Cancer”, and profitably stimulated the attention of the American company that decided to use, in their trial, the combination of drugs used by Camerino researchers in this study.
“The use of cannabinoids – continues Nabissi – is now considered effective in various diseases, including chronic pain, but it is also used as an antiemetic to reduce vomiting in patients undergoing chemotherapy, as anti-anorectic in the stimulation of appetite in patients with anorexia, as well as in some forms of glaucoma and in Multiple Sclerosis”.
https://www.researchitaly.it/en/success-stori...e-myeloma/
